Immune reconstruction inflammatory syndrome in HIV infection: beyond what meets the eye.

Q1 Medicine Topics in antiviral medicine Pub Date : 2020-01-01
Irini Sereti
{"title":"Immune reconstruction inflammatory syndrome in HIV infection: beyond what meets the eye.","authors":"Irini Sereti","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>A high proportion of individuals with HIV infection currently are diagnosed at an advanced stage of disease (late presenters), increasing their risk for immune reconstitution inflammatory syndrome (IRIS). IRIS typically occurs within 6 months of initiation of antiretroviral therapy (ART) in patients with low CD4+ cell counts and can occur before any marked elevation in CD4+ count is achieved on ART. In addition to low CD4+ count at ART initiation, 2 other major clinical predictors of IRIS are preexisting opportunistic infection (including subclinical infection) and shorter treatment period for opportunistic infection prior to starting ART. Mycobacterial infection-associated IRIS, including tuberculosis (TB)-associated IRIS, and cryptococcal infection-associated IRIS are the most common forms of the syndrome. Corticosteroid prophylaxis and early treatment can be effective in reducing incidence of TB-IRIS and severity of symptoms in select patients. Sterilization of the cerebrospinal fluid should be achieved prior to starting ART in patients with TB meningitis and cryptococcal meningitis. This article summarizes a presentation by Irini Sereti, MD, MHS, at the International Antiviral Society-USA (IAS-USA) continuing education program held in Washington, DC, in April 2019.</p>","PeriodicalId":38738,"journal":{"name":"Topics in antiviral medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162680/pdf/tam-27-106.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Topics in antiviral medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

A high proportion of individuals with HIV infection currently are diagnosed at an advanced stage of disease (late presenters), increasing their risk for immune reconstitution inflammatory syndrome (IRIS). IRIS typically occurs within 6 months of initiation of antiretroviral therapy (ART) in patients with low CD4+ cell counts and can occur before any marked elevation in CD4+ count is achieved on ART. In addition to low CD4+ count at ART initiation, 2 other major clinical predictors of IRIS are preexisting opportunistic infection (including subclinical infection) and shorter treatment period for opportunistic infection prior to starting ART. Mycobacterial infection-associated IRIS, including tuberculosis (TB)-associated IRIS, and cryptococcal infection-associated IRIS are the most common forms of the syndrome. Corticosteroid prophylaxis and early treatment can be effective in reducing incidence of TB-IRIS and severity of symptoms in select patients. Sterilization of the cerebrospinal fluid should be achieved prior to starting ART in patients with TB meningitis and cryptococcal meningitis. This article summarizes a presentation by Irini Sereti, MD, MHS, at the International Antiviral Society-USA (IAS-USA) continuing education program held in Washington, DC, in April 2019.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
HIV感染中的免疫重建炎症综合征:超越眼睛所见。
目前,很大比例的艾滋病毒感染者被诊断为疾病晚期(迟发者),这增加了他们患免疫重建炎症综合征(IRIS)的风险。IRIS通常发生在CD4+细胞计数低的患者开始抗逆转录病毒治疗(ART)后6个月内,也可能发生在抗逆转录病毒治疗后CD4+细胞计数明显升高之前。除了开始抗逆转录病毒治疗时CD4+计数低外,IRIS的另外两个主要临床预测因素是先前存在的机会性感染(包括亚临床感染)和开始抗逆转录病毒治疗前机会性感染的治疗时间较短。分枝杆菌感染相关的IRIS,包括结核(TB)相关的IRIS和隐球菌感染相关的IRIS是该综合征最常见的形式。皮质类固醇预防和早期治疗可有效降低某些患者的TB-IRIS发病率和症状严重程度。结核性脑膜炎和隐球菌性脑膜炎患者在开始抗逆转录病毒治疗前应对脑脊液进行灭菌。本文总结了Irini Sereti, MD, MHS在2019年4月于华盛顿特区举行的美国国际抗病毒学会(IAS-USA)继续教育项目上的演讲。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Topics in antiviral medicine
Topics in antiviral medicine Medicine-Pharmacology (medical)
CiteScore
1.80
自引率
0.00%
发文量
10
期刊最新文献
CROI 2024: Global Epidemiology and Prevention of HIV and Other Sexually Transmitted Diseases. CROI 2024: Metabolic and Other Complications of HIV Infection. CROI 2024: Summary of Basic Science Research in HIV. CROI 2024: Tuberculosis, Mpox, and Other Infectious Complications in People With HIV. Long-Term Effects of COVID-19: The Stories of 2 Physicians Who Became Patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1